<DOC>
	<DOCNO>NCT01451489</DOCNO>
	<brief_summary>This prospective , multicentre study compare efficacy , safety , tolerability relapse FK506 versus CTX treatment severe Focal Segmental Glomerulosclerosis ( FSGS ) .</brief_summary>
	<brief_title>The Efficacy Safety Tacrolimus Treated Refractory Focal Segmental Glomerulosclerosis</brief_title>
	<detailed_description>1 . Using response rate completely response time compare efficacy FK506 versus CTX therapy severe FSGS patient . 2 . To compare safety tolerability FK506 versus CTX severe FSGS patient .</detailed_description>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>patient diagnosis FSGS . Patients proteinuria ≥ 3.5g/24h , blood albumin &lt; 30g/L , Scr〈 2.3 mg/dl eGFR &gt; 30ml/min per 1.73m2 . Patients sign write informed consent form ( patient less 18 year old parents/legal representative 's signature ) , give consent follow study procedure followup . Patients receive treatment FK506 late 2 month cumulative dose CTX≥6 g. Patients know allergic macrolide . Patients active hepatitis . Patients impaired liver function , ALT/GPT AST/GOT twice normal upper limit . Patients blood leukocyte &lt; 3000/ul . Patients kidney disease family history Patients 2 type diabetes . Patients obesity whose BMI &gt; 28kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>FSGS</keyword>
	<keyword>FK506</keyword>
	<keyword>CTX</keyword>
</DOC>